Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Geron Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its revenue outlook and product performance [1][5]. Group 1: Class Action Details - The class action is filed for securities purchased between June 7, 2024, and February 25, 2025, and investors may be entitled to compensation without upfront costs through a contingency fee arrangement [1][2]. - Interested parties can join the class action by contacting Rosen Law Firm, with a deadline to serve as lead plaintiff set for May 12, 2025 [3][6]. Group 2: Allegations Against Geron Corporation - The lawsuit alleges that Geron Corporation made false and misleading statements regarding its product Rytelo, creating an inaccurate perception of its market potential and revenue growth while downplaying risks associated with seasonality and competition [5]. - The claims suggest that the actual market performance of Rytelo was significantly below expectations, with challenges in market penetration and competition impacting patient starts more than previously indicated [5].

Core Insights - A class action has been filed against Geron Corporation on behalf of investors who acquired its securities between June 7, 2024, and February 25, 2025, due to alleged misleading information regarding the launch and growth potential of its product Rytelo [1][2]. Company Overview - Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancer treatment, with its primary product being a telomerase inhibitor named imetelstat, marketed as Rytelo [1]. Allegations - The complaint claims that Geron misled investors by presenting overly optimistic reports about Rytelo's launch success and growth potential, failing to disclose significant factors such as seasonality, competition, and the burden of monitoring that affected patient starts [2]. - It is alleged that Rytelo lacked sufficient market awareness, hindering Geron's ability to meet the significant unmet need for the drug, especially among first-line patients and those outside academic settings [2]. Financial Impact - On February 26, 2025, Geron announced its fourth-quarter financial results for fiscal 2024, revealing that Rytelo's growth had stagnated. The company attributed this to seasonality, competition, lack of awareness, and monitoring requirements [3]. - Following this announcement, Geron's stock price plummeted from $2.37 per share on February 25, 2025, to $1.61 per share on February 26, 2025, marking a decline of approximately 32.07% in one day [3].

Core Viewpoint - Geron Corporation is facing a class action lawsuit for alleged violations of the Securities Exchange Act of 1934, with claims that the company and its executives misled investors regarding the performance and market potential of its primary product, Rytelo [1][3]. Group 1: Class Action Details - The class action lawsuit, titled Dabestani v. Geron Corporation, allows purchasers of Geron securities from June 7, 2024, to February 25, 2025, to seek appointment as lead plaintiff by May 12, 2025 [1][5]. - The lawsuit alleges that Geron made false statements about its revenue outlook and growth potential, downplaying risks associated with seasonality and competition [3][4]. - Geron's primary product, Rytelo, is a telomerase inhibitor, which has reportedly struggled to gain market awareness and penetration, impacting its sales performance [2][3]. Group 2: Financial Impact - On February 26, 2025, Geron reported that Rytelo's growth had flattened, attributing this to seasonality, competition, and lack of market awareness, leading to a stock price decline of over 32% [4]. - The lawsuit claims that the optimistic projections made by Geron were not reflective of the actual market conditions and challenges faced by the product [3][4]. Group 3: Legal Representation - Robbins Geller Rudman & Dowd LLP is representing investors in this class action lawsuit, noted for its significant recoveries in securities fraud cases, including over $2.5 billion in 2024 alone [6]. - The firm has a strong track record in securities class action recoveries, having secured the largest recovery in history at $7.2 billion in the Enron case [6].

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Geron Corporation ("Geron" or the "Company") (NASDAQ:GERN). The investigation concerns whether Geron and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On February 26, 2025, Geron announced its financial results for the fourth year and full year 2024. During a related earnings ...

NEW YORK, Feb. 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Geron Corporation ("Geron" or the "Company") (NASDAQ: GERN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Geron and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On February 26, 2025, Geron ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 000-20859 GERON CORPORATION (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporat ...

Core Insights - The analysis emphasizes a conservative investment strategy, allocating 90% to stable investments and 10% to growth opportunities for balanced returns [1] - A detailed valuation framework is presented, projecting free cash flows over a 9-year period with a focus on consistent annual growth rates and discounting cash flows using CAPM [1] - The pharmaceutical revenue model outlines market adoption starting at 12.5% and reaching 100% by peak sales, with a significant decline in penetration post-exclusivity [1] Valuation Framework - The base valuation framework projects free cash flows over a 9-year period, starting from a baseline year, applying consistent annual growth rates [1] - Cash flows are discounted using a rate calculated through CAPM, considering both time value and risk factors [1] - Terminal value is calculated by projecting Year 9 cash flows and applying a sustainable long-term growth rate, assuming steady growth patterns [1] Pharmaceutical Revenue Model - The model assumes market adoption begins at 12.5% penetration at launch, growing linearly to 100% by the peak sales year [1] - Post-exclusivity, penetration drops sharply by 80% in the first year and declines by 5% annually thereafter [1] - Revenue is calculated by multiplying the number of patients by the annual treatment cost, with costs scaling proportionally with revenue [1]

Geron Corporation (NASDAQ:GERN) Q4 2024 Earnings Conference Call February 26, 2025 8:00 AM ET Company Participants Aron Feingold - VP of IR and Corporate Communications John Scarlett - Chairman and CEO Michelle Robertson - EVP and CFO Jim Ziegler - EVP and CCO Joseph Eid - EVP, R&D Faye Feller - EVP and CMO Conference Call Participants Peter Lawson - Barclays Tara Bancroft - TD Cowen Faisal Khurshid - Leerink Partners Greg Harrison - Scotiabank Stephen Willey - Stifel Emily Bodnar - H.C. Wainwright Kalpit P ...

Q4 and Full Year 2024 Earnings Call February 26, 2025 Welcome and Introduction JOHN SCARLETT, M.D. Chairman of the Board, President and Chief Executive Officer MICHELLE ROBERTSON Executive Vice President, Chief Financial Officer and Treasurer JIM ZIEGLER Executive Vice President, Chief Commercial Officer JOSEPH EID, M.D. Executive Vice President, Research and Development FAYE FELLER, M.D. Executive Vice President, Chief Medical Officer 2 Forward-Looking Statements During the course of this presentation and ...

Company Performance - Geron reported a quarterly loss of $0.04 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.02, representing an earnings surprise of -100% [1] - The company posted revenues of $47.54 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 4.67%, compared to revenues of $0.02 million in the same quarter last year [2] - Over the last four quarters, Geron has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] Stock Movement and Outlook - Geron shares have declined approximately 33.1% since the beginning of the year, while the S&P 500 has gained 1.3% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the coming quarter at -$0.04 on revenues of $57.3 million, and -$0.07 on revenues of $297.85 million for the current fiscal year [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Geron belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Geron's stock performance [5]